挥发性麻醉药与丙泊酚在体外循环心脏手术中的比较:随机试验的荟萃分析
该系统评价与荟萃分析纳入42项随机研究共8197例体外循环心脏手术成人患者,比较挥发性麻醉药与丙泊酚对短期和长期死亡率及主要临床事件的影响。结果示挥发性麻醉药组1年死亡率、心肌梗死、肌钙蛋白释放、正性肌力药需求、拔管时间及心脏指数等指标优于丙泊酚,短期死亡率和急性肾损伤无差异。
要点
- 挥发性麻醉药较丙泊酚降低体外循环心脏手术患者1年死亡率(5.5% vs. 6.8%,OR 0.76)。
- 挥发性麻醉药减少心肌梗死、肌钙蛋白释放和正性肌力药需求,并缩短拔管时间。
- 短期死亡率和急性肾损伤在两组间无显著差异。
核心结论
- 在体外循环心脏手术成人患者中,挥发性麻醉药在长期死亡率和多项提示心肌保护的次要结局方面优于丙泊酚。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Cochrane Library及文章参考文献列表(1965年至2019年9月30日),纳入37篇全文(42项研究,8197例参与者)的随机临床试验。
主要发现
- 挥发性麻醉药组1年死亡率为5.5%,丙泊酚组为6.8%(OR 0.76,95%CI 0.60-0.96,P=0.023)。
- 挥发性麻醉药组心肌梗死OR 0.60(95%CI 0.39-0.92,P=0.023),肌钙蛋白释放SMD -0.39(95%CI -0.59至-0.18,P=0.0002)。
- 挥发性麻醉药组正性肌力药需求OR 0.40(95%CI 0.24-0.67,P=0.0004),拔管时间SMD -0.35(95%CI -0.68至-0.02,P=0.038)。
- 挥发性麻醉药组心脏指数/输出SMD 0.70(95%CI 0.37-1.04,P<0.0001)。
- 短期死亡率(1.63% vs. 1.65%,OR 1.04,95%CI 0.73-1.49,P=0.820)和急性肾损伤(OR 1.25,95%CI 0.77-2.03,P=0.358)两组无显著差异。
临床怎么用
- 对于体外循环心脏手术成人患者,可优先选用挥发性麻醉药维持麻醉,以降低1年死亡率和心肌损伤指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this systematic review and meta-analysis was to assess the effect of anesthesia maintenance with volatile agents compared with propofol on both short- and long-term mortality (primary outcomes) and major clinical events in adults undergoing cardiac surgery with cardiopulmonary bypass. METHODS: Randomized clinical trials on the effects of current volatile anesthetics versus propofol in adults undergoing cardiac surgery with cardiopulmonary bypass were searched (1965 to September 30, 2019) in PubMed, the Cochrane Library, and article reference lists. A random effect model on standardized mean difference for continuous outcomes and odds ratio for dichotomous outcomes were used to meta-analyze data. RESULTS: In total, 37 full-text articles (42 studies, 8,197 participants) were included. The class of volatile anesthetics compared with propofol was associated with lower 1-yr mortality (5.5 vs. 6.8%; odds ratio, 0.76 [95% CI, 0.60 to 0.96]; P = 0.023), myocardial infarction (odds ratio, 0.60 [95% CI, 0.39 to 0.92]; P = 0.023), cardiac troponin release (standardized mean difference, -0.39 [95% CI, -0.59 to -0.18], P = 0.0002), need for inotropic medications (odds ratio, 0.40 [95% CI, 0.24 to 0.67]; P = 0.0004), extubation time (standardized mean difference, -0.35 [95% CI, -0.68 to -0.02]; P = 0.038), and with higher cardiac index/output (standardized mean difference, 0.70 [95% CI, 0.37 to 1.04]; P < 0.0001). The class of volatile anesthetics was not associated with changes in short-term mortality (1.63 vs. 1.65%; odds ratio, 1.04 [95% CI, 0.73 to 1.49]; P = 0.820) and acute kidney injury (odds ratio, 1.25 [95% CI, 0.77 to 2.03]; P = 0.358). CONCLUSIONS: In adults undergoing cardiac surgery with cardiopulmonary bypass, the class of volatile anesthetics was superior to propofol with regard to long-term mortality, as well as to many secondary outcomes indicating myocardial protection.
引用
- Bonanni A, Signori A, Alicino C, et al. Volatile Anesthetics versus Propofol for Cardiac Surgery with Cardiopulmonary Bypass: Meta-analysis of Randomized Trials. Anesthesiology. 2020. PMID: 32205551. doi:10.1097/ALN.0000000000003236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。